Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Clinical trial NCT00136604 · COMPLETED

Trial details

NCT number: NCT00136604
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Whole Cell Pertussis Haemophilus Influenzae Type b Hepatitis B Diphtheria Tetanus Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Start date: 2006-01-22
Primary completion: 2006-04-23
Enrollment: 617

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.